Navigation Links
Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
Date:5/22/2012

NEWTON, Mass., May 22, 2012 /PRNewswire/ -- Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that it has received financial support totaling $1.1 million from 12 not-for-profit foundations serving the muscular dystrophy patient community. Halo will use the funds to expedite the phase 2 study of HT-100, its lead drug candidate for Duchenne muscular dystrophy (DMD). HT-100, a proprietary formulation of halofuginone, is an orally available small molecule drug candidate being developed to reduce fibrosis and promote healthy muscle fiber regeneration in DMD patients. Halo will begin its phase 2 study in the second half of 2012.

"Companies typically labor for years to attract the level of engagement we have received from such an active, dedicated patient advocacy community," said Marc Blaustein, CEO of Halo Therapeutics. "We are both humbled and heartened by their support and believe that together we are better able to speed the delivery of new therapies for DMD to patients and their families."

DMD is a progressive and fatal neuromuscular disorder, which afflicts approximately 1 in 3,500 boys worldwide. There is currently no treatment. Muscle fibrosis is a primary outcome and ultimately leads to early patient death: Young men with DMD typically live into their twenties or early thirties. In studies, HT-100 has demonstrated potent ability to halt and reverse existing muscle fibrosis as well as promote the growth of healthy new muscle. In an independent review, an international advisory committee of neuromuscular disease experts concluded HT-100 was "ready for the clinic." The drug candidate has received Orphan status in both the U.S. and the EU.

"The community of muscular dystrophy foundations has rallied around our novel and aggressive approach to delivering a promising therapy to DMD boys and their families," said Tom Wicka, founder of the Nash Avery Foundation and father of Nash, age 12. "This level of unification and engagement across the patient advocacy community for an early-stage drug candidate is extremely rare, and we are grateful for the support and vision of our funding partners."

Added Benjamin Seckler, M.D., president of Charley's Fund and father of Charley, age 11: "We have the ultimate drive to get this done quickly: Our children's lives are at stake. We do not have the option of accepting the pace of typical drug development efforts. We thank our foundation partners and value their role in helping us further the development of HT-100 as rapidly as possible."

The foundations providing support include:

Action Duchenne
Coalition Duchenne
Cure Duchenne
Duchenne Now
Duchenne Research Fund
Hope for Gus
Hope for Javier
Jain Foundation
Michael's Cause
Parent Project Muscular Dystrophy
Ryan's Quest
Zubin's Wish

About Duchenne Muscular DystrophyDuchenne muscular dystrophy is caused by a mutation in the dystrophin gene, resulting in progressive muscle weakness. The disease manifests itself first in weakened skeletal muscles and eventually results in cardiac and pulmonary impairment. Corticosteroids are the current standard of care treatment for DMD.  While this treatment delays disease progression by several years, their prolonged use is typically associated with side effects and the treatment does not alter the ultimate outcome of the disease.

About Halo TherapeuticsBased in Newton, Mass., Halo Therapeutics, LLC, is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for rare fibrotic diseases like Duchenne muscular dystrophy. Founded through a collaboration between patient advocacy organizations and industry veterans, the company is partnering with the clinical community and patients to transform therapeutic options and, by extension, lives. For more information, please visit www.halotherapeutics.com.Media Contact:Name:

Marc B. BlausteinCompany:

Halo Therapeutics, LLC617.431.7250mblaustein@halotherapeutics.com


'/>"/>

SOURCE Halo Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
Breaking Medicine News(10 mins):